Minerva Neurosciences, Inc. 8-K

What Happened

• Minerva Neurosciences (NERV) filed an 8‑K reporting that Geoffrey Race resigned as President of the Company and as a director of its wholly‑owned subsidiary Mind‑NRG, effective March 31, 2026. The parties executed a Settlement Agreement dated March 30, 2026 that provides separation payments and other benefits.
• The Company announced and the Board appointed James O'Connor as Chief Business Officer and General Counsel, effective April 21, 2026. The Company also entered a Consultancy Agreement with Mr. Race that begins April 15, 2026 and runs through April 14, 2027 unless earlier terminated.

Key Details

• Settlement/Severance: one‑time payment equal to Mr. Race’s annual salary; 12 months’ pension contributions; pro‑rated 2026 bonus entitlement; one‑time severance of £30,000; 12 months’ private medical and life assurance contributions in lieu; reimbursement of legal fees up to £15,000 plus VAT.
• Equity treatment: all outstanding stock options held by Mr. Race were treated as fully vested as of March 31, 2026 and the exercise period for those options is extended until midnight (ET) on January 1, 2030.
• Consultancy terms: consulting fees of £333 per hour, minimum 35 hours per month (minimum monthly fee £11,655); consulting period April 15, 2026–April 14, 2027; options may be granted at the Compensation Committee’s discretion.
• Disclosure: press release dated April 2, 2026 was furnished with the 8‑K.

Why It Matters

• Leadership change: the departure of the Company’s President and appointment of a new Chief Business Officer & General Counsel are material executive changes that affect management continuity and corporate governance.
• Financial and equity impact: the settlement includes cash and benefits (specified pounds amounts for some items) and accelerated vesting plus an extended exercise window for options, which could affect potential share issuance if options are exercised. The consultancy agreement creates a predictable short‑term cash obligation (minimum monthly cost ~£11,655) and provides the company access to Mr. Race’s services during the transition.
• Investors should note the dates, cash amounts disclosed, and the extended option exercise deadline (Jan 1, 2030) when considering potential dilution and near‑term corporate costs.